AcelRx Pharmaceuticals Announces It Will Not Further Revise Its Offer to Acquire Tetraphase
AcelRx Pharmaceuticals Announces It Will Not Further Revise Its Offer to Acquire Tetraphase AcelRx to be paid a break-up fee of $1.8 million upon termination of the merger agreement by Tetraphase |
[03-June-2020] |
REDWOOD CITY, Calif., June 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it does not intend to revise further its offer under the terms of its previously announced agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) (NASDAQ: TTPH), and it expects the agreement to be terminated by Tetraphase. On June 1, 2020, Tetraphase disclosed that its board of directors had determined that an amended proposal from Melinta Therapeutics, Inc. constituted a "Superior Offer" under the terms of the AcelRx Merger Agreement. Under the terms of the agreement, in connection with a termination of the merger agreement, AcelRx will be paid a break-up fee of approximately $1.8 million. Vince Angotti, Chief Executive Officer at AcelRx said, "AcelRx is financially disciplined, and while we continue to recognize the merits of an AcelRx and Tetraphase combination, we do not believe that any further increases to our offer would be in the best interests of our stockholders. As a result, we have decided not to further increase our offer and will focus on other exciting opportunities to expand and diversify our product portfolio and create a platform for growth with other potential collaboration partners." The co-promotion agreement between AcelRx and Tetraphase (or any successor to Tetraphase) remains in place – safeguarded by significant financial obligations. The training of both the AcelRx and Tetraphase teams is complete and co-promotion efforts for DSUVIA® and XERAVA™ are currently underway. About AcelRx Pharmaceuticals, Inc. For additional information about AcelRx, please visit www.acelrx.com. Forward-Looking Statements
View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-it-will-not-further-revise-its-offer-to-acquire-tetraphase-301070465.html SOURCE AcelRx Pharmaceuticals, Inc. | ||
Company Codes: NASDAQ-NMS:ACRX, NASDAQ-NMS:TTPH |
© 2020 PR Newswire. All Rights Reserved.